Pharvaris Reports Positive Phase 3 Results for Deucrictibant IR, Plans H1 2026 NDA Submission, and Secures €160M Financing
Summary
Pharvaris N.V. reported positive pivotal Phase 3 results for its on-demand HAE treatment, Deucrictibant IR, with an NDA submission planned for H1 2026, alongside a successful €160.3 million financing round and ongoing progress in its prophylactic and AAE clinical programs.
Key Events
-
Positive Phase 3 Results for Deucrictibant IR
The RAPIDe-3 pivotal Phase 3 study for Deucrictibant IR capsules in on-demand HAE treatment met its primary and all 11 key secondary efficacy endpoints with statistical significance, demonstrating rapid and sustained symptom relief.
-
Planned NDA Submission in H1 2026
Following the successful RAPIDe-3 results, Pharvaris N.V. plans to submit a New Drug Application (NDA) to the U.S. FDA in the first half of 2026 for Deucrictibant IR.
-
Successful €160.3 Million Equity Financing
In July 2025, the company completed an underwritten offering of ordinary shares and pre-funded warrants, generating net proceeds of €160.3 million (approximately $188.5 million).
-
Strong Cash Position and Runway
As of December 31, 2025, Pharvaris held €291.7 million in cash and cash equivalents, which management believes is sufficient to fund operations for at least twelve months.
Analysis
Pharvaris N.V.'s annual report highlights significant progress in its clinical pipeline and a strengthened financial position. The company announced positive pivotal Phase 3 results for Deucrictibant IR capsules for on-demand treatment of HAE attacks, meeting all primary and key secondary efficacy endpoints with statistical significance. This success paves the way for a New Drug Application (NDA) submission to the FDA in the first half of 2026, a critical de-risking event for their lead candidate. Additionally, Pharvaris successfully completed a substantial underwritten offering in July 2025, raising €160.3 million (approximately $188.5 million) in net proceeds, which significantly bolsters its cash reserves to €291.7 million as of December 31, 2025. This financing, representing a substantial portion of the company's market capitalization, provides a runway of at least twelve months to fund ongoing operations and advance its clinical programs. The company also continues to progress its prophylactic (CHAPTER-3) and acquired angioedema (CREAATE) Phase 3 studies. While the net loss increased to €175.7 million in 2025, this is typical for a clinical-stage biopharmaceutical company heavily investing in R&D. The positive clinical data and robust financing are strong indicators of the company's advancement towards commercialization.
At the time of this filing, PHVS was trading at $27.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $11.51 to $29.85. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.